1353734-12-9
1353734-12-9
Chemical Structure
TBI-166
- CAS No.: 1353734-12-9
- Formula:C32H30F3N5O3
- Molecular Weight:589.61
IUPAC Name: 2-cyclohexyl-3,3,3-trifluoro-2-hydroxypropanoic acid
InChIKey: GUSGYHIQYWRCQO-QOSQFQCFSA-N
SMILES: FC(F)(F)OC1=CC=C(N2C3=C/C(C(NC4=CC=CN=C4OC)=CC3=NC5=C2C=CC=C5)=N/C6CCC(OC)CC6)C=C1
Biological Activity: TBI-166, a riminophenazine analogue, is an orally active anti-tuberculosis agent with fewer adverse reactions than the lead riminophenazine compound, Clofazimine (HY-B1046) [1][2][3].
| Cat. No. | Nom du produit | Pureté | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
TBI-166 | 99.78% | TBI-166, a riminophenazine analogue, is an orally active anti-tuberculosis agent with fewer adverse reactions than the lead riminophenazine compound, Clofazimine (HY-B1046) . | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Xu J, et al. In Vitro and In Vivo Activities of the Riminophenazine TBI-166 against Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2019 Apr 25;63(5):e02155-18. [Content Brief]
- [2]. Zhu H, et al. Activity of Clofazimine and TBI-166 against Mycobacterium tuberculosis in Different Administration Intervals in Mouse Tuberculosis Models. Antimicrob Agents Chemother. 2021 Mar 18;65(4):e02164-20. [Content Brief]
- [3]. Ding Y, et al. Superior Efficacy of a TBI-166, Bedaquiline, and Pyrazinamide Combination Regimen in a Murine Model of Tuberculosis. Antimicrob Agents Chemother. 2022 Sep 20;66(9):e0065822. [Content Brief]
Keywords
